Please assess the completion status of the following clinical trial:

Trial Title: Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Only female patients are eligible~2. Patients must be 18 years of age or older~3. Patients must have Androgenic Alopecia Grade I-II by Ludwig Classification~4. Patients must have been on stable birth control if premenopausal.~5. Patients are able and willing to provide written informed consent after the nature of the study is fully explained~Exclusion Criteria:~1. Patients with clinically abnormal hematology, serum chemistry, or screening laboratory results as reviewed by the Principal Investigator~2. Patients who have undergone topical and systemic therapies for hair loss 3 months prior to the procedure~3. Patients who have used any cosmetic product meant to address hair loss 3 months prior to enrollment~4. Patients taking anti-rheumatic disease medication (including methotrexate or other anti-metabolites) within the 3 months prior to study entry.~5. Patients previously having undergone hair transplant surgery prior to study entry~6. Patients who are pregnant or currently breast-feeding children as Rogaine for Women is contra indicated for these women~7. Patients who have taken spironolactone in the 3 months prior to study participation~8. Patients with systemic, rheumatic or inflammatory disease or who are immunosuppressed~9. Patients with ongoing infectious disease, including HIV and hepatitis~10. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes~11. Patients participating in a study of an experimental drug or medical device within 30 days of study entry~12. Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer in the last 5 years.~13. Patients taking antiaggregating therapy~14. Patients on anticoagulant therapy~15. Patients with tendency to keloid formation~16. Patients with uncompensated diabetes~17. Patients with active skin disease or skin infection at intended treatment areas

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Platelet Rich Plasma first, then Minoxidil Foam (Type: EXPERIMENTAL): Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
- Minoxidil Foam first, then Platelet Rich Plasma (Type: EXPERIMENTAL): Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.

Based on this trial design, predict the completion outcome and termination type (if applicable).